JP2016503065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503065A5 JP2016503065A5 JP2015549784A JP2015549784A JP2016503065A5 JP 2016503065 A5 JP2016503065 A5 JP 2016503065A5 JP 2015549784 A JP2015549784 A JP 2015549784A JP 2015549784 A JP2015549784 A JP 2015549784A JP 2016503065 A5 JP2016503065 A5 JP 2016503065A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 146
- 235000001014 amino acid Nutrition 0.000 claims 64
- 150000001413 amino acids Chemical class 0.000 claims 64
- 239000002773 nucleotide Substances 0.000 claims 60
- 125000003729 nucleotide group Chemical group 0.000 claims 60
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 54
- 239000012634 fragment Substances 0.000 claims 54
- 108010026424 tau Proteins Proteins 0.000 claims 54
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000018737 Parkinson disease Diseases 0.000 claims 7
- 208000034799 Tauopathies Diseases 0.000 claims 7
- 230000000626 neurodegenerative effect Effects 0.000 claims 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 6
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 3
- 210000000349 chromosome Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 102100034452 Alternative prion protein Human genes 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000004434 Calcinosis Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 206010018341 Gliosis Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000002308 calcification Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 230000007387 gliosis Effects 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002161 motor neuron Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 235000004400 serine Nutrition 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 230000002739 subcortical effect Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 102000043676 human tau 40 Human genes 0.000 claims 1
- 108700043385 human tau 40 Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745410P | 2012-12-21 | 2012-12-21 | |
| US61/745,410 | 2012-12-21 | ||
| PCT/US2013/076952 WO2014100600A2 (en) | 2012-12-21 | 2013-12-20 | Human anti-tau antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503065A JP2016503065A (ja) | 2016-02-01 |
| JP2016503065A5 true JP2016503065A5 (enExample) | 2016-09-01 |
| JP6284548B2 JP6284548B2 (ja) | 2018-02-28 |
Family
ID=49920689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549784A Expired - Fee Related JP6284548B2 (ja) | 2012-12-21 | 2013-12-20 | ヒト抗タウ抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9598484B2 (enExample) |
| EP (2) | EP3792278A3 (enExample) |
| JP (1) | JP6284548B2 (enExample) |
| KR (1) | KR102234324B1 (enExample) |
| CN (2) | CN111205368B (enExample) |
| AU (1) | AU2013361107B2 (enExample) |
| BR (1) | BR112015014751A8 (enExample) |
| CA (1) | CA2896066C (enExample) |
| CY (1) | CY1123518T1 (enExample) |
| DK (1) | DK2935326T3 (enExample) |
| EA (1) | EA035932B1 (enExample) |
| ES (1) | ES2816700T3 (enExample) |
| HR (1) | HRP20201422T1 (enExample) |
| HU (1) | HUE051320T2 (enExample) |
| IL (1) | IL239556B (enExample) |
| LT (1) | LT2935326T (enExample) |
| MX (1) | MX2015008024A (enExample) |
| MY (1) | MY184251A (enExample) |
| PH (2) | PH12015501420A1 (enExample) |
| PL (1) | PL2935326T3 (enExample) |
| PT (1) | PT2935326T (enExample) |
| RS (1) | RS60899B1 (enExample) |
| SG (2) | SG11201504822VA (enExample) |
| SI (1) | SI2935326T1 (enExample) |
| SM (1) | SMT202000512T1 (enExample) |
| WO (1) | WO2014100600A2 (enExample) |
| ZA (1) | ZA201504898B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011315181B2 (en) | 2010-10-11 | 2016-07-28 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| AU2013286680B2 (en) | 2012-07-03 | 2018-07-05 | Washington University | Antibodies to tau |
| WO2014043480A1 (en) | 2012-09-13 | 2014-03-20 | Crystal Ronald G | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| KR102313513B1 (ko) | 2013-03-13 | 2021-10-15 | 프로테나 바이오사이언시즈 리미티드 | Tau 면역치료제 |
| US20160355573A1 (en) * | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| EP3160999B1 (en) * | 2014-06-26 | 2018-11-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| DE102014013571A1 (de) * | 2014-09-18 | 2016-03-24 | Aj Roboscreen Gmbh | Monoklonaler Antikörper gegen humanes TAU-Protein |
| ES2848376T3 (es) | 2014-11-19 | 2021-08-09 | Axon Neuroscience Se | Anticuerpos de tau humanizados en la enfermedad de Alzheimer |
| EP3261670A4 (en) | 2015-02-24 | 2018-08-01 | Rpeptide, LLC | Anti-tau antibodies |
| AR103713A1 (es) * | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
| CA2986942C (en) | 2015-06-05 | 2025-07-22 | Ac Immune Sa | Anti-tau antibodies and their methods of use |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| EP3430397B1 (en) | 2016-03-14 | 2022-02-23 | Biogen International Neuroscience GmbH | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
| JP7194985B2 (ja) * | 2016-05-02 | 2022-12-23 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| JP7170316B2 (ja) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
| WO2017191560A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP2019517540A (ja) | 2016-06-07 | 2019-06-24 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | アルツハイマー病を治療する方法 |
| WO2018022479A1 (en) | 2016-07-25 | 2018-02-01 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
| JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
| KR20230146126A (ko) * | 2016-12-07 | 2023-10-18 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| EP3562840A1 (en) | 2016-12-16 | 2019-11-06 | Biogen MA Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| SG10201911225WA (en) | 2017-03-28 | 2020-01-30 | Genentech Inc | Methods of treating neurodegenerative diseases |
| CA3055866A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Methods for detection of tau protein aggregation modulating compounds |
| US11958896B2 (en) * | 2017-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
| TWI809562B (zh) | 2017-10-16 | 2023-07-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| US11629183B2 (en) | 2017-12-29 | 2023-04-18 | University Of Florida Research Foundation, Inc. | Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo |
| US10591492B2 (en) * | 2018-03-05 | 2020-03-17 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| CN111918875A (zh) * | 2018-03-11 | 2020-11-10 | 库罗什·沙帕桑 | 构象-特异性的抗神经毒性tau蛋白的抗体 |
| CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
| US20210347868A1 (en) * | 2018-10-19 | 2021-11-11 | Gabriel Pascual | Anti-synuclein antibodies |
| AU2019371814A1 (en) | 2018-10-29 | 2021-06-17 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| JOP20210098A1 (ar) * | 2018-11-08 | 2023-01-30 | Prothena Biosciences Ltd | أجسام مضادة تتعرف على تاو |
| KR102905634B1 (ko) * | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
| WO2020252394A2 (en) * | 2019-06-13 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia |
| JP2022547781A (ja) * | 2019-07-23 | 2022-11-16 | シャンハイテック ユニバーシティ | Ａｓｉｃ１チャネルアンタゴニスト抗体 |
| CN114641490B (zh) | 2019-08-06 | 2023-06-06 | 新旭生技股份有限公司 | 结合至病理性tau种类的抗体及其用途 |
| JP7243851B2 (ja) * | 2019-10-25 | 2023-03-22 | 東洋紡株式会社 | レーザー印字可能なフィルムおよびそれを用いた包装体 |
| WO2021262791A1 (en) | 2020-06-25 | 2021-12-30 | Merck Sharp & Dohme Corp. | High affinity antibodies targeting tau phosphorylated at serine 413 |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| JP2023548632A (ja) * | 2020-10-26 | 2023-11-17 | ソラ・バイオサイエンシズ・エルエルシー | アルツハイマー病の処置のための組成物および方法 |
| CN117043183A (zh) * | 2020-12-16 | 2023-11-10 | 沃雅戈治疗公司 | Tau结合化合物 |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| AU2022332303A1 (en) | 2021-08-27 | 2024-02-01 | Genentech, Inc. | Methods of treating tau pathologies |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| KR20240162497A (ko) | 2022-03-14 | 2024-11-15 | 제넨테크, 인크. | 음성 분석에 기반한 신경퇴행성 질환 예측 |
| CA3259777A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | DETECTION OF LONGITUDINAL PROGRESSION OF ALZHEIMER'S DISEASE, BASED ON VOICE ANALYSIS |
| CA3266790A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | TAU PROTEIN BINDING COMPOUNDS |
| WO2025090985A1 (en) * | 2023-10-27 | 2025-05-01 | Duke University | Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof |
| CN117946264B (zh) * | 2024-03-21 | 2024-06-04 | 江西赛基生物技术有限公司 | 一种抗Tau蛋白单克隆抗体及其应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| FI895955A0 (fi) | 1988-04-15 | 1989-12-13 | Protein Design Labs Inc | Il-2-receptorspecifika chimera antikroppar. |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| DK0574395T3 (da) | 1990-11-09 | 2002-10-07 | Stephen D Gillies | Cytokin-immunkonjugater |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| CA2121599C (en) | 1991-10-25 | 2007-04-10 | Marc Mercken | Monoclonal antibodies directed against the microtubule-associated protein tau |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| EP0627932B1 (en) | 1992-11-04 | 2002-05-08 | City Of Hope | Antibody construct |
| DE669986T1 (de) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5843779A (en) | 1992-12-14 | 1998-12-01 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies |
| US6008024A (en) | 1993-12-21 | 1999-12-28 | Innogenetics, N.V. | Monoclonal antibodies specific for PHF-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
| JPH10506381A (ja) | 1994-07-29 | 1998-06-23 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用 |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| ES2242997T3 (es) | 1997-03-14 | 2005-11-16 | Biogen Idec Inc. | Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo. |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO2000030680A1 (en) | 1998-11-23 | 2000-06-02 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| DE60126130T2 (de) | 2000-11-17 | 2007-10-18 | The University Of Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| CN1494553A (zh) | 2001-01-29 | 2004-05-05 | IDECҩ�﹫˾ | 改变的抗体及其使用方法 |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| CA2456121A1 (en) | 2001-08-03 | 2003-02-20 | Medical Research Council | Intracellular antibodies |
| US20050015819A1 (en) | 2001-08-24 | 2005-01-20 | Jurgen Gotz | Method of inducing the formation of neurofibrillary tangles in transgenic animals |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| AU2003257850A1 (en) | 2002-08-14 | 2004-03-03 | Mitsubishi Kagaku Iatron, Inc. | ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN |
| US20060240485A1 (en) | 2003-04-24 | 2006-10-26 | Universitat Zurich | Method of monitoring immunotherapy |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
| US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| ES2641897T3 (es) | 2007-01-05 | 2017-11-14 | University Of Zurich | Procedimiento para proporcionar moléculas de unión y diana específicas de una enfermedad |
| SG10201804513WA (en) * | 2008-04-25 | 2018-07-30 | Dyax Corp | Antibodies Against Fcrn And Use Thereof |
| CN101307108B (zh) * | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途 |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| WO2011053565A2 (en) * | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| ES2548686T3 (es) * | 2010-10-07 | 2015-10-20 | Ac Immune S.A. | Anticuerpos que reconocen fosfo-Tau |
| AU2011315181B2 (en) | 2010-10-11 | 2016-07-28 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| WO2012106363A2 (en) * | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012149365A2 (en) | 2011-04-27 | 2012-11-01 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
-
2013
- 2013-12-20 US US14/654,176 patent/US9598484B2/en not_active Expired - Fee Related
- 2013-12-20 WO PCT/US2013/076952 patent/WO2014100600A2/en not_active Ceased
- 2013-12-20 EA EA201591020A patent/EA035932B1/ru unknown
- 2013-12-20 CA CA2896066A patent/CA2896066C/en active Active
- 2013-12-20 SG SG11201504822VA patent/SG11201504822VA/en unknown
- 2013-12-20 CN CN201911004609.5A patent/CN111205368B/zh not_active Expired - Fee Related
- 2013-12-20 RS RS20201060A patent/RS60899B1/sr unknown
- 2013-12-20 EP EP20178431.1A patent/EP3792278A3/en not_active Withdrawn
- 2013-12-20 MY MYPI2015001581A patent/MY184251A/en unknown
- 2013-12-20 EP EP13818637.4A patent/EP2935326B1/en active Active
- 2013-12-20 LT LTEP13818637.4T patent/LT2935326T/lt unknown
- 2013-12-20 SI SI201331780T patent/SI2935326T1/sl unknown
- 2013-12-20 SG SG10201705104UA patent/SG10201705104UA/en unknown
- 2013-12-20 PT PT138186374T patent/PT2935326T/pt unknown
- 2013-12-20 JP JP2015549784A patent/JP6284548B2/ja not_active Expired - Fee Related
- 2013-12-20 DK DK13818637.4T patent/DK2935326T3/da active
- 2013-12-20 CN CN201380073531.7A patent/CN105324394B/zh not_active Expired - Fee Related
- 2013-12-20 KR KR1020157019330A patent/KR102234324B1/ko not_active Expired - Fee Related
- 2013-12-20 BR BR112015014751A patent/BR112015014751A8/pt not_active IP Right Cessation
- 2013-12-20 SM SM20200512T patent/SMT202000512T1/it unknown
- 2013-12-20 PL PL13818637.4T patent/PL2935326T3/pl unknown
- 2013-12-20 MX MX2015008024A patent/MX2015008024A/es active IP Right Grant
- 2013-12-20 HU HUE13818637A patent/HUE051320T2/hu unknown
- 2013-12-20 HR HRP20201422TT patent/HRP20201422T1/hr unknown
- 2013-12-20 ES ES13818637T patent/ES2816700T3/es active Active
- 2013-12-20 AU AU2013361107A patent/AU2013361107B2/en not_active Ceased
-
2015
- 2015-06-19 PH PH12015501420A patent/PH12015501420A1/en unknown
- 2015-06-21 IL IL239556A patent/IL239556B/en active IP Right Grant
- 2015-07-08 ZA ZA201504898A patent/ZA201504898B/en unknown
-
2017
- 2017-02-08 US US15/427,843 patent/US20170369560A1/en not_active Abandoned
-
2018
- 2018-06-27 US US16/020,346 patent/US20190169274A1/en not_active Abandoned
-
2019
- 2019-09-24 US US16/580,152 patent/US20200262895A1/en not_active Abandoned
-
2020
- 2020-09-09 CY CY20201100854T patent/CY1123518T1/el unknown
-
2021
- 2021-01-13 PH PH12021550083A patent/PH12021550083A1/en unknown